ATE510559T1 - Imunogene bakterielle vesikeln mit äussere membranproteine - Google Patents
Imunogene bakterielle vesikeln mit äussere membranproteineInfo
- Publication number
- ATE510559T1 ATE510559T1 AT05801788T AT05801788T ATE510559T1 AT E510559 T1 ATE510559 T1 AT E510559T1 AT 05801788 T AT05801788 T AT 05801788T AT 05801788 T AT05801788 T AT 05801788T AT E510559 T1 ATE510559 T1 AT E510559T1
- Authority
- AT
- Austria
- Prior art keywords
- bacterium
- outer membrane
- membrane proteins
- provides
- vesicles
- Prior art date
Links
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 title 1
- 241000894006 Bacteria Species 0.000 abstract 4
- 241000588724 Escherichia coli Species 0.000 abstract 2
- 101150084069 mltA gene Proteins 0.000 abstract 2
- 241000588722 Escherichia Species 0.000 abstract 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 abstract 1
- 101100043703 Mus musculus Sting1 gene Proteins 0.000 abstract 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract 1
- 241000040340 Oat mosaic virus Species 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 108010013639 Peptidoglycan Proteins 0.000 abstract 1
- RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002101 lytic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0424092.5A GB0424092D0 (en) | 2004-10-29 | 2004-10-29 | Immunogenic bacterial vesicles with outer membrane proteins |
| PCT/IB2005/003494 WO2006046143A2 (en) | 2004-10-29 | 2005-10-28 | Immunogenic bacterial vesicles with outer membrane proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510559T1 true ATE510559T1 (de) | 2011-06-15 |
Family
ID=33515801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05801788T ATE510559T1 (de) | 2004-10-29 | 2005-10-28 | Imunogene bakterielle vesikeln mit äussere membranproteine |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9206399B2 (de) |
| EP (2) | EP2279747B1 (de) |
| JP (4) | JP5362221B2 (de) |
| CN (1) | CN101048175B (de) |
| AT (1) | ATE510559T1 (de) |
| AU (1) | AU2005298332B2 (de) |
| BR (1) | BRPI0517514A8 (de) |
| CA (1) | CA2584778C (de) |
| CY (1) | CY1112105T1 (de) |
| ES (1) | ES2507499T3 (de) |
| GB (1) | GB0424092D0 (de) |
| NZ (1) | NZ553989A (de) |
| PL (1) | PL2279747T3 (de) |
| PT (1) | PT2279747E (de) |
| WO (1) | WO2006046143A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0010721A (pt) | 1999-05-19 | 2002-06-11 | Chiron Spa | Composições de neisserias combinadas |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| NZ580974A (en) * | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| EP1872791A1 (de) * | 2006-06-30 | 2008-01-02 | Institut Pasteur | Verwendung von Polysacchariden bakteriellen Ursprungs zur Hemmung der Bildung von Biofilmen |
| EP2586790A3 (de) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogene von uropathogenen Escherichia coli |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| GB0816284D0 (en) * | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
| EP2367568A2 (de) | 2008-12-17 | 2011-09-28 | Novartis AG | Meningokokken-impfstoffe mit hämoglobin-rezeptor |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| AU2010302344A1 (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| JP5860402B2 (ja) * | 2009-10-08 | 2016-02-16 | イオン メディックス インコーポレイテッド | 室内空気由来細胞外ベシクルを含む組成物及びその用途 |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| PL3831406T3 (pl) | 2010-08-23 | 2024-09-09 | Wyeth Llc | Stabilne preparaty antygenów rLP2086 Neisseria meningitidis |
| GB201014967D0 (en) * | 2010-09-09 | 2010-10-20 | Univ Southampton | Composition |
| ES2759484T3 (es) | 2010-09-10 | 2020-05-11 | Glaxosmithkline Biologicals Sa | Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo |
| RU2546873C2 (ru) | 2010-09-10 | 2015-04-10 | УАЙТ ЭлЭлСи | Нелипидизированные варианты антигенов neisseria meningitidis orf2086 |
| EP2707009A1 (de) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyretika zur verbesserung der verträglichkeit von impfstoffen auf vesikelbasis |
| CA2847621A1 (en) * | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| BR112014019166A2 (pt) | 2012-02-02 | 2017-07-04 | Novartis Ag | promotores para expressão aumentada de proteína em meningococos |
| EP2823312B1 (de) | 2012-03-08 | 2019-08-07 | GlaxoSmithKline Biologicals SA | In vitro-wirksamkeits basierte assay für protein-basierten meningokokken-impfstoffe |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| WO2013186753A1 (en) | 2012-06-14 | 2013-12-19 | Novartis Ag | Vaccines for serogroup x meningococcus |
| BR112015005056A2 (pt) | 2012-09-06 | 2017-11-21 | Novartis Ag | vacinas de combinação com sorogrupo b meningococcus e d/t/p |
| EP4056198A3 (de) * | 2012-09-18 | 2022-12-07 | GlaxoSmithKline Biologicals SA | Aussenmembranvesikel |
| EP2953620A1 (de) | 2013-02-07 | 2015-12-16 | GlaxoSmithKline Biologicals SA | Pharmazeutische zusammensetzungen mit vesikeln |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| EP4098276A1 (de) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis-zusammensetzungen und verfahren dafür |
| AU2015222121B2 (en) | 2014-02-28 | 2018-01-18 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3263695A1 (de) | 2016-06-29 | 2018-01-03 | GlaxoSmithKline Biologicals SA | Immunogene zusammensetzungen |
| CA3035320A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
| CN108220267B (zh) * | 2016-12-22 | 2022-10-04 | 丰益(上海)生物技术研发中心有限公司 | 磷脂酶及其应用 |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| MX2020002659A (es) | 2017-09-08 | 2020-09-09 | Evelo Biosciences Inc | Vesiculas extracelulares bacterianas. |
| AU2018379236B2 (en) * | 2017-12-04 | 2025-02-27 | Intravacc B.V. | An improved process for producing outer membrane vesicles |
| EP3607967A1 (de) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modifizierte meningokokken fhbp polypeptide |
| CN113646438A (zh) * | 2019-01-11 | 2021-11-12 | 西北大学 | 在原核生物细胞裂解物中合成生物缀合物疫苗 |
| MX2021010160A (es) * | 2019-02-22 | 2021-09-14 | Evelo Biosciences Inc | Preparaciones de membrana bacteriana. |
| WO2021059181A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3799884A1 (de) * | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogene zusammensetzungen |
| CN111440748A (zh) * | 2020-05-15 | 2020-07-24 | 黑龙江八一农垦大学 | 一种分离、提纯及鉴定坏死杆菌外膜囊泡的方法 |
| WO2022123063A2 (en) * | 2020-12-11 | 2022-06-16 | Glaxosmithkline Biologicals Sa | Hyper-blebbing bacteria |
| GB202115077D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Assay |
| WO2023097652A1 (en) * | 2021-12-03 | 2023-06-08 | National Center For Nanoscience And Technology | An engineered cell and application thereof |
| GB202211033D0 (en) | 2022-07-28 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Purification process |
| CN116410899B (zh) * | 2023-04-14 | 2024-10-15 | 中国科学院武汉病毒研究所 | 利用裂解酶LysP53产生细菌外膜囊泡的方法及应用 |
| CN118853525B (zh) * | 2024-09-26 | 2025-01-07 | 上海羽冠生物技术有限公司 | 经修饰的百日咳鲍特菌菌株 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| NZ230423A (en) | 1988-08-25 | 1993-08-26 | Liposome Co Inc | A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| WO1990006696A2 (en) | 1988-12-19 | 1990-06-28 | Praxis Biologics, Inc. | Meningococcal class 1 outer-membrane protein vaccine |
| EP0378881B1 (de) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| US5993826A (en) | 1993-03-02 | 1999-11-30 | Board Of Regents, The University Of Texas | Methods and compositions relating to useful antigens of moraxella catarrhalis |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
| EP0689454B2 (de) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| DE69423383T2 (de) | 1993-05-13 | 2000-08-24 | American Cyanamid Co., Wayne | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP0710118B1 (de) | 1994-04-20 | 1998-11-25 | U.S. Department Of The Army | Impfstoff gegen gram-negative bakterielle infektionen |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| BR9609882A (pt) | 1995-08-04 | 1999-07-27 | Univ Guelph | Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| KR20010021953A (ko) | 1997-07-17 | 2001-03-15 | 추후제출 | Ｂ군 수막염균 포린 및 에이치.인플루엔자 다당류를포함하는 면역원성 접합체 |
| JP2001514001A (ja) | 1997-08-21 | 2001-09-11 | オランダ国 | グラム陰性粘膜細菌の新規突然変異株及びそのワクチンにおける応用 |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| ES2278420T3 (es) | 1997-11-21 | 2007-08-01 | Serono Genetics Institute S.A. | Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion. |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| CN1280619A (zh) | 1997-11-28 | 2001-01-17 | 根瑟特公司 | 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染 |
| WO1999040936A2 (en) | 1998-02-12 | 1999-08-19 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
| ES2278446T3 (es) | 1998-05-29 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Vacunas combinadas b/c contra la meningitis. |
| EP1741443B1 (de) | 1998-05-29 | 2014-05-21 | Novartis Vaccines and Diagnostics, Inc. | Kombinierte Meningitis B/C Impfstoffe |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| ATE386541T1 (de) | 1999-02-22 | 2008-03-15 | Health Prot Agency | Neisseria impfstoffzusammensetzungen und methoden |
| KR100642044B1 (ko) | 1999-03-19 | 2006-11-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| EP1165796A2 (de) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Rekombinantes clostridium-toxin a als proteinträger für polysaccharidkonjugatimpstoffen |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| BR0014285A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico |
| PL355163A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| WO2001034642A2 (en) | 1999-11-12 | 2001-05-17 | University Of Iowa Research Foundation | Control of neisserial membrane synthesis |
| CA2871789C (en) | 2000-01-17 | 2017-04-04 | Novartis Vaccines And Diagnostics S.R.L. | Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins |
| WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| ES2281409T3 (es) | 2000-02-28 | 2007-10-01 | Novartis Vaccines And Diagnostics S.R.L. | Expresion heterologa de proteinas de neisseria. |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| GB0017149D0 (en) | 2000-07-12 | 2000-08-30 | Chiron Spa | Helicobacter pylori mutants |
| JP5511117B2 (ja) * | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| US7939087B2 (en) | 2000-10-27 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from Streptococcus groups A & B |
| GB0103171D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| WO2003009869A1 (en) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| DE20321889U1 (de) | 2002-08-02 | 2012-03-12 | Glaxosmithkline Biologicals S.A. | Impfstoffzusammensetzung |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| DK2353608T3 (da) | 2002-10-11 | 2020-02-10 | Novartis Vaccines And Diagnostics S R L | Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer |
| DK2279746T3 (da) | 2002-11-15 | 2013-11-25 | Novartis Vaccines & Diagnostic | Overfladeproteiner i neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| AU2003288558A1 (en) | 2002-12-16 | 2004-07-09 | Nasjonalt Folkehelseinstitutt | Meningococcal vaccine based on outer membrane proteins porb2 and pora |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| JP5173194B2 (ja) | 2003-12-23 | 2013-03-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| SI2682126T1 (sl) | 2005-01-27 | 2017-03-31 | Children's Hospital & Research Center At Oakland | Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom |
| WO2009158142A1 (en) | 2008-05-30 | 2009-12-30 | The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| GB0816284D0 (en) | 2008-09-05 | 2008-10-15 | Nat Biolog Standards Board | Vaccine |
-
2004
- 2004-10-29 GB GBGB0424092.5A patent/GB0424092D0/en not_active Ceased
-
2005
- 2005-10-28 US US11/666,786 patent/US9206399B2/en not_active Expired - Fee Related
- 2005-10-28 BR BRPI0517514A patent/BRPI0517514A8/pt not_active Application Discontinuation
- 2005-10-28 EP EP10183544.5A patent/EP2279747B1/de not_active Expired - Lifetime
- 2005-10-28 AT AT05801788T patent/ATE510559T1/de not_active IP Right Cessation
- 2005-10-28 ES ES10183544.5T patent/ES2507499T3/es not_active Expired - Lifetime
- 2005-10-28 PL PL10183544T patent/PL2279747T3/pl unknown
- 2005-10-28 WO PCT/IB2005/003494 patent/WO2006046143A2/en not_active Ceased
- 2005-10-28 AU AU2005298332A patent/AU2005298332B2/en not_active Ceased
- 2005-10-28 NZ NZ553989A patent/NZ553989A/en not_active IP Right Cessation
- 2005-10-28 CN CN2005800368277A patent/CN101048175B/zh not_active Expired - Fee Related
- 2005-10-28 PT PT101835445T patent/PT2279747E/pt unknown
- 2005-10-28 CA CA2584778A patent/CA2584778C/en not_active Expired - Fee Related
- 2005-10-28 JP JP2007538548A patent/JP5362221B2/ja not_active Expired - Fee Related
- 2005-10-28 EP EP05801788A patent/EP1804834B1/de not_active Expired - Lifetime
-
2011
- 2011-07-01 JP JP2011147317A patent/JP2011188870A/ja active Pending
- 2011-08-18 CY CY20111100796T patent/CY1112105T1/el unknown
-
2013
- 2013-11-29 JP JP2013246917A patent/JP6077983B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-29 US US14/927,052 patent/US9771399B2/en not_active Expired - Fee Related
-
2016
- 2016-04-25 JP JP2016086917A patent/JP2016135139A/ja active Pending
-
2017
- 2017-09-07 US US15/698,434 patent/US10336794B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101048175A (zh) | 2007-10-03 |
| US20100015212A1 (en) | 2010-01-21 |
| AU2005298332A1 (en) | 2006-05-04 |
| JP2014039566A (ja) | 2014-03-06 |
| EP2279747B1 (de) | 2014-06-25 |
| JP2008517617A (ja) | 2008-05-29 |
| JP2011188870A (ja) | 2011-09-29 |
| US9771399B2 (en) | 2017-09-26 |
| PL2279747T3 (pl) | 2015-01-30 |
| PT2279747E (pt) | 2014-10-02 |
| BRPI0517514A8 (pt) | 2017-10-03 |
| NZ553989A (en) | 2010-03-26 |
| US20160108094A1 (en) | 2016-04-21 |
| US20180009852A1 (en) | 2018-01-11 |
| WO2006046143A3 (en) | 2007-03-15 |
| US10336794B2 (en) | 2019-07-02 |
| CN101048175B (zh) | 2013-03-13 |
| JP2016135139A (ja) | 2016-07-28 |
| JP5362221B2 (ja) | 2013-12-11 |
| CY1112105T1 (el) | 2015-11-04 |
| CA2584778A1 (en) | 2006-05-04 |
| CA2584778C (en) | 2014-04-08 |
| AU2005298332B2 (en) | 2012-05-03 |
| EP2279747A1 (de) | 2011-02-02 |
| WO2006046143A2 (en) | 2006-05-04 |
| JP6077983B2 (ja) | 2017-02-08 |
| EP1804834B1 (de) | 2011-05-25 |
| ES2507499T3 (es) | 2014-10-15 |
| EP1804834A2 (de) | 2007-07-11 |
| US9206399B2 (en) | 2015-12-08 |
| BRPI0517514A (pt) | 2008-10-14 |
| GB0424092D0 (en) | 2004-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE510559T1 (de) | Imunogene bakterielle vesikeln mit äussere membranproteine | |
| BRPI0417825A (pt) | métodos para uso de lactobacilli probióticos para animais de estimação | |
| PT1261723E (pt) | Expressões híbridas de proteínas de neisseria | |
| MXPA03002683A (es) | Cepas de escherichia coli las cuales sobreproducen l-treonina y procedimientos para produccion de l-treonina mediante fermentacion.. | |
| AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
| DE60122881D1 (de) | Nicht-lebensfähigen lactobacillus enthaltendes lebensmittelprodukt | |
| ATE303070T1 (de) | Herstellung von nahrungsmitteln durch fermentierung von sojamilch mit streptococcus thermophilus | |
| ATE354964T1 (de) | Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen | |
| EA200700870A1 (ru) | Лиофилизированные препараты молочно-кислых бактерий и бифидобактерий с высокой степенью дисперсности | |
| ATE529123T1 (de) | Synthetische glykolipopeptide als impfstoffe | |
| Martelet et al. | Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants | |
| IL156942A0 (en) | Compounds, pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia | |
| WO2004099235A3 (en) | Bacteriocins and novel bacterial strains | |
| AU2002217043A1 (en) | Salmonella vaccine | |
| NZ590603A (en) | Method for preparation of lactic acid bacterium having anti-allergic activity comprising culturing bacterium in casein hydrolysate | |
| DE69925585D1 (de) | Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff | |
| ATE544471T1 (de) | Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen | |
| ATE299177T1 (de) | Milchsäurebakterien und ihre anwendung zur herstellung von hypercholesterolemische aktive produkte | |
| PT1131080E (pt) | Seleccao e utilizacoes de estirpes de bacterias lacticas moduladoras da imunidade nao-especifica | |
| BRPI0410444A (pt) | processo e inóculo para fermentação láctica acidificante | |
| WO2006132944A3 (en) | Probiotic system for aquaculture | |
| ATE301938T1 (de) | Neuer bakterienstamm und seine verwendung | |
| EA200701730A1 (ru) | Бактериоцины и новые бактериальные штаммы | |
| RU2001135343A (ru) | Штамм бактерий Bifidobacterium longum 58B для приготовления биологически активных добавок, регулирующих микрофлору кишечника у детей раннего возраста | |
| EP1172434A4 (de) | Photosynthetische purpurbakterien und heilnahrungsmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |